Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Agents Intervening against Delirium in the Intensive Care Unit (AID-ICU) - Protocol for a randomised placebo-controlled trial of haloperidol in patients with delirium in the ICU

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. APACHE II score validation in emergency abdominal surgery. A post hoc analysis of the InCare trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Depth to the airway lumen at the level of the cricothyroid membrane measured by ultrasound

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effects of magnesium, phosphate and zinc supplementation in ICU patients-Protocol for a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

BACKGROUND: Delirium among patients in the intensive care unit (ICU) is a common condition associated with increased morbidity and mortality. Haloperidol is the most frequently used pharmacologic intervention, but its use is not supported by firm evidence. Therefore, we are conducting Agents Intervening against Delirium in the Intensive Care Unit (AID-ICU) trial to assess the benefits and harms of haloperidol for the treatment of ICU-acquired delirium.

METHODS: AID-ICU is an investigator-initiated, pragmatic, international, randomised, blinded, parallel-group, trial allocating adult ICU patients with manifest delirium 1:1 to haloperidol or placebo. Trial participants will receive intravenous 2.5 mg haloperidol three times daily or matching placebo (isotonic saline 0.9%) if they are delirious. If needed, a maximum of 20mg/daily haloperidol/placebo is given. An escape protocol, not including haloperidol, is part of the trial protocol. The primary outcome is days alive out of the hospital within 90 days post-randomisation. Secondary outcomes are number of days without delirium or coma, serious adverse reactions to haloperidol, usage of escape medication, number of days alive without mechanical ventilation; mortality, health-related-quality-of-life and cognitive function at 1-year-follow-up. A sample size of 1000 patients is required to detect a 7 day improvement or worsening of the mean days alive out of the hospital, type 1 error risk of 5% and power 90%.

PERSPECTIVE: The AID-ICU trial is based on gold standard methodology applied to a large sample of clinically representative patients and will provide pivotal high-quality data on the benefits and harms of haloperidol for the treatment ICU-acquired delirium.

Original languageEnglish
JournalActa Anaesthesiologica Scandinavica
Volume63
Issue number10
Pages (from-to)1426-1433
Number of pages8
ISSN0001-5172
DOIs
Publication statusPublished - Nov 2019

Bibliographical note

© 2019 Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

ID: 57655290